← Leaderboards
David P Skoner
Children'S Hosp Pittsburgh/Upmc Hlth Sys
$1,054,378
Attributed
$1,054,378
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $312K · FY2005–06$500K$375K$250K$125K$0
'05
'06
Funding mix
By agency
NIH$1,054,378 · 3
By mechanism
R01$1,053,810 · 1
M01$568 · 2
Top collaborators
No co-investigators on record.
Most similar at Children'S Hosp Pittsburgh/Upmc Hlth Sys
Same institution · by research overlap
- Ellen R. Wald$8,036,977
- William J Doyle$5,754,268
- Deborah A Gentile$622,211
- Cuneyt Metin Alper$5,139,585
- Judith M Martin$623,430
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectSecretionRespiratory ReflexRespiratory HypersensitivityDrug Screening /EvaluationRespiratory Disorder EpidemiologyRespiratory Disorder ChemotherapyInterleukin 6Inhalation Drug AdministrationHuman Therapy EvaluationInterleukin 10Clinical Trial Phase IInterleukin 1Interleukin 8Outcomes ResearchSign /SymptomGenetic SusceptibilityTriamcinoloneOsteocalcinOtitis MediaStressPreschool Child (1-5)Prognosis
Grant awards (8)
Immune Mechanisms of Middle Ear Disease$304,716
R01 · FY2006 · AI · contact PI
Immune Mechanisms of Middle Ear Disease$312,047
R01 · FY2005 · AI
Immune Mechanisms of Middle Ear Disease$324,547
R01 · FY2004 · AI
Effects of Long-Term Treatment with Intranasally Inhaled Triamcinolone Acetonide$568
M01 · FY2004 · RR
Immune Mechanisms of Middle Ear Disease$112,500
R01 · FY2003 · AI
EVALUATE EFFECT OF INTRANASALLY ADMINISTERED INTERLEUKINS$0
M01 · FY2002 · RR
EVALUATE EFFECT OF INTRANASALLY ADMINISTERED INTERLEUKINS$0
M01 · FY2001 · RR
EVALUATE EFFECT OF INTRANASALLY ADMINISTERED INTERLEUKINS$0
M01 · FY2000 · RR